Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy
Status:
Recruiting
Trial end date:
2023-11-30
Target enrollment:
Participant gender:
Summary
To explore the efficacy and safety of preoperative treatment of potentially resectable
locally advanced or recurrent metastatic gastrointestinal stromal tumor (GIST) after failure
of treatment.